147 related articles for article (PubMed ID: 35432811)
1. Development and immunohistochemical characterization of patient-derived xenograft models for muscle invasive bladder cancer.
Razzaghdoust A; Muhammadnejad S; Parvin M; Mofid B; Zangeneh M; Basiri A
Iran J Basic Med Sci; 2021 Dec; 24(12):1650-1655. PubMed ID: 35432811
[TBL] [Abstract][Full Text] [Related]
2. Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.
Jäger W; Xue H; Hayashi T; Janssen C; Awrey S; Wyatt AW; Anderson S; Moskalev I; Haegert A; Alshalalfa M; Erho N; Davicioni E; Fazli L; Li E; Collins C; Wang Y; Black PC
Oncotarget; 2015 Aug; 6(25):21522-32. PubMed ID: 26041878
[TBL] [Abstract][Full Text] [Related]
3. Patient-derived non-small cell lung cancer xenograft mirrors complex tumor heterogeneity.
Chen X; Shen C; Wei Z; Zhang R; Wang Y; Jiang L; Chen K; Qiu S; Zhang Y; Zhang T; Chen B; Xu Y; Feng Q; Huang J; Zhong Z; Li H; Che G; Xiao K
Cancer Biol Med; 2021 Feb; 18(1):184-198. PubMed ID: 33628593
[TBL] [Abstract][Full Text] [Related]
4. Characterizing treatment resistance in muscle invasive bladder cancer using the chicken egg chorioallantoic membrane patient-derived xenograft model.
Villanueva H; Wells GA; Miller MT; Villanueva M; Pathak R; Castro P; Ittmann MM; Sikora AG; Lerner SP
Heliyon; 2022 Dec; 8(12):e12570. PubMed ID: 36643309
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of
Ecke TH; Kiani A; Schlomm T; Friedersdorff F; Rabien A; Jung K; Kilic E; Boström P; Tervahartiala M; Taimen P; Gleichenhagen J; Johnen G; Brüning T; Koch S; Roggisch J; Wirtz RM
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050010
[TBL] [Abstract][Full Text] [Related]
6. Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient's response to conventional and novel therapies.
Liu L; Wu M; Huang A; Gao C; Yang Y; Liu H; Jiang H; Yu L; Huang Y; Wang H
J Transl Med; 2023 Sep; 21(1):611. PubMed ID: 37689699
[TBL] [Abstract][Full Text] [Related]
7. Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies.
Lang H; Béraud C; Cabel L; Fontugne J; Lassalle M; Krucker C; Dufour F; Groeneveld CS; Dixon V; Meng X; Kamoun A; Chapeaublanc E; De Reynies A; Gamé X; Rischmann P; Bieche I; Masliah-Planchon J; Beaurepere R; Allory Y; Lindner V; Misseri Y; Radvanyi F; Lluel P; Bernard-Pierrot I; Massfelder T
Front Oncol; 2022; 12():930731. PubMed ID: 36033544
[TBL] [Abstract][Full Text] [Related]
8. Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.
Chedgy EC; Douglas J; Wright JL; Seiler R; van Rhijn BW; Boormans J; Todenhöfer T; Dinney CP; Collins CC; Van der Heijden MS; Black PC
Urol Oncol; 2016 Oct; 34(10):469-76. PubMed ID: 27317490
[TBL] [Abstract][Full Text] [Related]
9. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.
Navone NM; van Weerden WM; Vessella RL; Williams ED; Wang Y; Isaacs JT; Nguyen HM; Culig Z; van der Pluijm G; Rentsch CA; Marques RB; de Ridder CMA; Bubendorf L; Thalmann GN; Brennen WN; Santer FR; Moser PL; Shepherd P; Efstathiou E; Xue H; Lin D; Buijs J; Bosse T; Collins A; Maitland N; Buzza M; Kouspou M; Achtman A; Taylor RA; Risbridger G; Corey E
Prostate; 2018 Dec; 78(16):1262-1282. PubMed ID: 30073676
[TBL] [Abstract][Full Text] [Related]
10. Association of immunohistochemical markers of tumor subtype with response to neoadjuvant chemotherapy and survival in patients with muscle-invasive bladder cancer.
Razzaghdoust A; Ghajari M; Basiri A; Torbati PM; Jafari A; Fattahi MR; Salahi M; Mofid B
Investig Clin Urol; 2021 May; 62(3):274-281. PubMed ID: 33943049
[TBL] [Abstract][Full Text] [Related]
11. Patient-derived bladder cancer xenograft models reveal VEGF and CDK4 enhancing tumor metastasis behavior.
Zhao Y; An M; Zhang H; Tan D; Chen X; Wu P; Qin W; Zhang C; Shi C
RSC Adv; 2019 Jun; 9(31):17877-17884. PubMed ID: 35520551
[TBL] [Abstract][Full Text] [Related]
12. Effects of siRNA Silencing of TUG1 and LCAL6 Long Non-coding RNAs on Patient-derived Xenograft of Non-small Cell Lung Cancer.
Fang T; Huang H; Li X; Liao J; Yang Z; Hoffman RM; Cheng XI; Liang L; Hu W; Yun S
Anticancer Res; 2018 Jan; 38(1):179-186. PubMed ID: 29277771
[TBL] [Abstract][Full Text] [Related]
13. KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer.
Jütte H; Reike M; Wirtz RM; Kriegmair M; Erben P; Tully K; Weyerer V; Eckstein M; Hartmann A; Eidt S; Wezel F; Bolenz C; Tannapfel A; Noldus J; Roghmann F
J Pers Med; 2021 May; 11(6):. PubMed ID: 34073233
[TBL] [Abstract][Full Text] [Related]
14. Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers.
Peng S; Creighton CJ; Zhang Y; Sen B; Mazumdar T; Myers JN; Lai SY; Woolfson A; Lorenzi MV; Bell D; Williams MD; Johnson FM
J Transl Med; 2013 Aug; 11():198. PubMed ID: 23981300
[TBL] [Abstract][Full Text] [Related]
15. Novel Patient Metastatic Pleural Effusion-Derived Xenograft Model of Renal Medullary Carcinoma Demonstrates Therapeutic Efficacy of Sunitinib.
Lee AQ; Ijiri M; Rodriguez R; Gandour-Edwards R; Lee J; Tepper CG; Li Y; Beckett L; Lam K; Goodwin N; Satake N
Front Oncol; 2021; 11():648097. PubMed ID: 33842362
[TBL] [Abstract][Full Text] [Related]
16. Preparation and application of patient-derived xenograft mice model of colorectal cancer.
Zhang Y; Yang Y; Zan L; Wang J; Yan L; Zhao L; Chen L; Xi Y; Bai W; Yang X
Iran J Basic Med Sci; 2023 Feb; 26(2):248-254. PubMed ID: 36742145
[TBL] [Abstract][Full Text] [Related]
17. Histologic and molecular analysis of patient derived xenografts of high-grade serous ovarian carcinoma.
Dong R; Qiang W; Guo H; Xu X; Kim JJ; Mazar A; Kong B; Wei JJ
J Hematol Oncol; 2016 Sep; 9(1):92. PubMed ID: 27655386
[TBL] [Abstract][Full Text] [Related]
18. Patient-derived xenograft models for gastrointestinal tumors: A single-center retrospective study.
Yu X; Chen Y; Lu J; He K; Chen Y; Ding Y; Jin K; Wang H; Zhang H; Wang H; Teng L
Front Oncol; 2022; 12():985154. PubMed ID: 36465411
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive comparison of patient-derived xenograft models in Hepatocellular Carcinoma and metastatic Liver Cancer.
Xu W; Zhao ZY; An QM; Dong B; Lv A; Li CP; Guan XY; Tian XY; Wu JH; Hao CY
Int J Med Sci; 2020; 17(18):3073-3081. PubMed ID: 33173428
[TBL] [Abstract][Full Text] [Related]
20. Establishment of Novel Gastric Cancer Patient-Derived Xenografts and Cell Lines: Pathological Comparison between Primary Tumor, Patient-Derived, and Cell-Line Derived Xenografts.
Kuwata T; Yanagihara K; Iino Y; Komatsu T; Ochiai A; Sekine S; Taniguchi H; Katai H; Kinoshita T; Ohtsu A
Cells; 2019 Jun; 8(6):. PubMed ID: 31207870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
